查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1600018

细胞和基因治疗临床试验市场：按类型、阶段、应用和最终用户划分 - 2025-2030 年全球预测

Cell & Gene Therapy Clinical Trials Market by Type (Cell Therapy Clinical Trials, Gene Therapy Clinical Trials), Phase (Phase I, Phase II, Phase III), Application, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

细胞与基因治疗临床试验市场2023年估值为92亿美元，预计2024年将达到104.8亿美元，复合年增长率为14.61%，2030年将达239.1亿美元。

细胞和基因疗法是临床试验的前沿发展，重点是基因层面的治疗、预防和潜在治癒方法。这些治疗方法涵盖从肿瘤学到罕见遗传疾病，并提供了改变疾病治疗通讯协定的潜力。这些治疗方法需要透过独特的机制来解决疾病的根本原因，而不是仅仅缓解症状，从而为复杂和慢性疾病的永续长期管理和治癒铺平道路。这些治疗方法的最终用途包括医院、专科治疗中心和研究机构，并跨越医疗保健和生物技术等多个领域。市场的主要亮点是由于技术进步和法规环境改善，製药公司、生物技术公司和学术机构之间的投资和合作激增。随着慢性病的增加和人口老化，对创新疗法的需求不断增加，商机也随之增加。然而，挑战仍然存在，例如研发成本上升、复杂的监管环境以及製造和物流障碍，这些都阻碍了市场的成长。此外，缺乏适当的报销架构和对熟练劳动力的需求也是主要限制因素。持续专注于创新至关重要，载体设计、CRISPR 等基因编辑技术以及可扩展的生产方法还有很大的改进空间，以提高治疗效果并降低成本。随着大型製药企业收购小型生技公司以加强其产品线和能力组合，市场的性质倾向于整合。为了取得成功，我们必须重视研发策略伙伴关係，投资尖端製造技术，并倡导个人化医疗方法。儘早与监管机构接触以优化临床试验设计并探索多种监管途径可以简化市场进入和扩张。

主要市场统计
基准年[2023] 92亿美元
预测年份 [2024] 104.8亿美元
预测年份 [2030] 239.1亿美元
复合年增长率（%） 14.61%

市场动态：快速发展的细胞和基因治疗临床试验市场的关键市场洞察

细胞和基因治疗临床试验市场正因供需的动态交互作用而转变。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 扩大细胞和基因疗法在癌症研究的应用
    • 世界各地慢性病的盛行率正在上升
    • 生物製药公司对细胞研究的投资活动增加
  • 市场限制因素
    • 安全有效地将基因导入人体技术的复杂性
  • 市场机会
    • 政府监管机构对细胞和基因疗法的批准增加
    • 更多采用先进技术进行细胞和基因治疗临床试验
  • 市场挑战
    • 与患者对治疗反应的可变性相关的问题

波特的五力：驾驭细胞与基因治疗临床试验市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解外部对细胞和基因治疗临床试验市场的影响

外部宏观环境因素在塑造细胞和基因治疗临床试验市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解细胞/基因疗法临床试验市场的竞争状况

细胞和基因治疗临床试验市场的详细市场占有率分析提供了对供应商绩效的全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示自己的竞争定位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位、基质细胞和基因治疗临床试验市场供应商绩效评估

FPNV定位矩阵是评估细胞和基因治疗临床试验市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议 绘製细胞和基因治疗临床试验市场的成功之路

对于希望加强在全球市场的影响力的公司来说，细胞和基因治疗临床试验市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 扩大细胞和基因疗法在癌症研究的应用
      • 世界各地慢性病盛行率正在上升
      • 生物製药公司对细胞研究的投资活动增加
    • 抑制因素
      • 安全有效地将基因传送到人体的技术复杂性
    • 机会
      • 政府对细胞和基因疗法的监管核准增加
      • 扩大细胞和基因治疗临床试验中先进技术的采用
    • 任务
      • 与患者对治疗反应的可变性相关的问题
  • 市场区隔分析
    • 类型：同种异体细胞疗法在癌症和遗传性疾病治疗中的重要性日益增加
    • 最终用户：效率和扩充性提高了合约研究组织对细胞和基因治疗临床试验的采用
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章 细胞/基因治疗临床试验市场：依类型

  • 细胞疗法临床试验
    • 同种异体细胞疗法
    • 自体细胞疗法
    • CAR-T细胞疗法
    • 间质干细胞治疗
  • 基因治疗临床试验
    • 基于反义寡核苷酸的基因治疗
    • 基于 CRISPR 的基因治疗
    • 非病毒载体基因治疗
    • 病毒载体基因治疗

第七章 细胞/基因治疗临床试验市场分阶段

  • 第一阶段
  • 第二阶段
  • 第三阶段
  • 第四阶段

第八章 细胞/基因治疗临床试验市场：依应用分类

  • 心臟病学
  • 皮肤科
  • 内分泌、代谢、遗传学
  • 胃肠病学
  • 血液学
  • 免疫学和发炎
  • 感染疾病
  • 肌肉骨骼
  • 神经病学
  • 肿瘤学
  • 眼科

第九章细胞/基因治疗临床试验市场：依最终使用者分类

  • 学术研究所
  • 合约研究组织（CRO）
  • 医院和诊所
  • 製药公司

第十章美洲细胞与基因治疗临床试验市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太细胞与基因治疗临床试验市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲细胞和基因治疗临床试验市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • 辛辛那提儿童医院耗资 6000 万美元在沙伦维尔开设应用基因和细胞治疗中心
    • Premier Investigations 与 BioCentric 之间的策略联盟加快了创新细胞疗法的预 IND 申请时间表和临床转化
    • Astellas来向 Poseida Therapeutics 投资 5000 万美元，用于癌细胞疗法的独家许可和开发
  • 战略分析和建议

公司名单

  • Accell Clinical Research, LLC
  • Alnylam Pharmaceuticals, Inc.
  • Amgen Inc.
  • Atlant Clinical Ltd.
  • Biogen Inc.
  • Charles River Laboratories International, Inc.
  • CORESTEM, Inc.
  • CTI Clinical Trial and Consulting Services, Inc.
  • Dendreon Pharmaceuticals LLC
  • HELIXMITH Co., Ltd.
  • ICON PLC
  • IQVIA Inc.
  • Kolon TissueGene, Inc.
  • Laboratory Corporation of America Holdings
  • Medpace Holdings, Inc.
  • Novartis AG
  • Novotech Pty Limited
  • Parexel International Corporation
  • Ppd, Inc.
  • ProPharma Group Holdings, LLC
  • PSI CRO
  • SGS SA
  • Syneos Health, Inc.
  • Veristat, LLC
  • Wuxi AppTec Inc.
Product Code: MRR-0D217D5AEB5A

The Cell & Gene Therapy Clinical Trials Market was valued at USD 9.20 billion in 2023, expected to reach USD 10.48 billion in 2024, and is projected to grow at a CAGR of 14.61%, to USD 23.91 billion by 2030.

Cell and gene therapies represent cutting-edge developments in clinical trials focused on treating, preventing, or potentially curing condition-drivers at the genetic level. The scope of these therapies extends from oncology to rare genetic disorders, offering transformative potential in disease treatment protocols. These therapies are necessary due to their unique mechanisms that address root causes of diseases rather than merely alleviating symptoms, paving the way for sustainable, long-term management or cure of complex and chronic conditions. Application of these therapies spans multiple sectors, including healthcare and biotechnology, with end-use in hospitals, specialized treatment centers, and research institutions. Market insights highlight a surge in investment and collaborations between pharmaceutical companies, biotech firms, and academic institutions driven by technological advancements and supportive regulatory environments, which act as key growth influencers. Opportunities are abundant with increasing incidences of chronic diseases and an aging population, driving the demand for innovative treatments. However, challenges persist, such as high R&D costs, complex regulatory landscapes, and manufacturing and logistical hurdles, which can impede market growth. Additionally, the lack of appropriate reimbursement frameworks and the need for skilled workforce pose significant limitations. Focus on continuous innovation is essential, with ample scope for improvements in vector design, gene editing technologies like CRISPR, and scalable production methods to enhance therapy efficacy and reduce costs. The nature of the market leans towards consolidation, as larger pharmaceutical entities acquire smaller biotechs to bolster pipelines and capability portfolios. To thrive, businesses should focus on strategic partnerships for R&D, invest in cutting-edge manufacturing technologies, and champion personalized medicine approaches. Engaging with regulatory bodies early for optimizing trial designs and seeking versatile regulatory pathways could ease market entry and expansion, while targeting niche markets with high unmet needs would provide a competitive edge.

KEY MARKET STATISTICS
Base Year [2023] USD 9.20 billion
Estimated Year [2024] USD 10.48 billion
Forecast Year [2030] USD 23.91 billion
CAGR (%) 14.61%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cell & Gene Therapy Clinical Trials Market

The Cell & Gene Therapy Clinical Trials Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing application of cell & gene therapy in cancer research
    • Rising prevalence of chronic disease across the globe
    • Increasing investment activities by biopharmaceutical companies for cell-based research
  • Market Restraints
    • Technological complexity of delivering genes into the human body safely and effectively
  • Market Opportunities
    • Growing regulatory approvals from the government for cell & gene therapies
    • Increasing adoption of advanced technologies for cell & gene therapy clinical trials
  • Market Challenges
    • Issues associated with variability in patient responses to therapies

Porter's Five Forces: A Strategic Tool for Navigating the Cell & Gene Therapy Clinical Trials Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cell & Gene Therapy Clinical Trials Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cell & Gene Therapy Clinical Trials Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cell & Gene Therapy Clinical Trials Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cell & Gene Therapy Clinical Trials Market

A detailed market share analysis in the Cell & Gene Therapy Clinical Trials Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cell & Gene Therapy Clinical Trials Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cell & Gene Therapy Clinical Trials Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cell & Gene Therapy Clinical Trials Market

A strategic analysis of the Cell & Gene Therapy Clinical Trials Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cell & Gene Therapy Clinical Trials Market, highlighting leading vendors and their innovative profiles. These include Accell Clinical Research, LLC, Alnylam Pharmaceuticals, Inc., Amgen Inc., Atlant Clinical Ltd., Biogen Inc., Charles River Laboratories International, Inc., CORESTEM, Inc., CTI Clinical Trial and Consulting Services, Inc., Dendreon Pharmaceuticals LLC, HELIXMITH Co., Ltd., ICON PLC, IQVIA Inc., Kolon TissueGene, Inc., Laboratory Corporation of America Holdings, Medpace Holdings, Inc., Novartis AG, Novotech Pty Limited, Parexel International Corporation, Ppd, Inc., ProPharma Group Holdings, LLC, PSI CRO, SGS S.A., Syneos Health, Inc., Veristat, LLC, and Wuxi AppTec Inc..

Market Segmentation & Coverage

This research report categorizes the Cell & Gene Therapy Clinical Trials Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Cell Therapy Clinical Trials and Gene Therapy Clinical Trials. The Cell Therapy Clinical Trials is further studied across Allogeneic Cell Therapy, Autologous Cell Therapy, CAR-T Cell Therapy, and Mesenchymal Stem Cell Therapy. The Gene Therapy Clinical Trials is further studied across Antisense Oligonucleotide-Based Gene Therapy, CRISPR-Based Gene Therapy, Non-Viral Vector Gene Therapy, and Viral Vector Gene Therapy.
  • Based on Phase, market is studied across Phase I, Phase II, Phase III, and Phase IV.
  • Based on Application, market is studied across Cardiology, Dermatology, Endocrine, Metabolic, & Genetic, Gastroenterology, Hematology, Immunology & Inflammation, Infectious Diseases, Musculoskeletal, Neurology, Oncology, and Ophthalmology.
  • Based on End-User, market is studied across Academic & Research Institutes, Contract Research Organizations (CROs), Hospitals and Clinics, and Pharmaceutical Companies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing application of cell & gene therapy in cancer research
      • 5.1.1.2. Rising prevalence of chronic disease across the globe
      • 5.1.1.3. Increasing investment activities by biopharmaceutical companies for cell-based research
    • 5.1.2. Restraints
      • 5.1.2.1. Technological complexity of delivering genes into the human body safely and effectively
    • 5.1.3. Opportunities
      • 5.1.3.1. Growing regulatory approvals from the government for cell & gene therapies
      • 5.1.3.2. Increasing adoption of advanced technologies for cell & gene therapy clinical trials
    • 5.1.4. Challenges
      • 5.1.4.1. Issues associated with variability in patient responses to therapies
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Rising significance of allogeneic cell therapy in the treatment of cancers and genetic disorders
    • 5.2.2. End-User: Increasing application of cell & gene therapy clinical trials in contract research organizations due to their efficiency and scalability
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Cell & Gene Therapy Clinical Trials Market, by Type

  • 6.1. Introduction
  • 6.2. Cell Therapy Clinical Trials
    • 6.2.1. Allogeneic Cell Therapy
    • 6.2.2. Autologous Cell Therapy
    • 6.2.3. CAR-T Cell Therapy
    • 6.2.4. Mesenchymal Stem Cell Therapy
  • 6.3. Gene Therapy Clinical Trials
    • 6.3.1. Antisense Oligonucleotide-Based Gene Therapy
    • 6.3.2. CRISPR-Based Gene Therapy
    • 6.3.3. Non-Viral Vector Gene Therapy
    • 6.3.4. Viral Vector Gene Therapy

7. Cell & Gene Therapy Clinical Trials Market, by Phase

  • 7.1. Introduction
  • 7.2. Phase I
  • 7.3. Phase II
  • 7.4. Phase III
  • 7.5. Phase IV

8. Cell & Gene Therapy Clinical Trials Market, by Application

  • 8.1. Introduction
  • 8.2. Cardiology
  • 8.3. Dermatology
  • 8.4. Endocrine, Metabolic, & Genetic
  • 8.5. Gastroenterology
  • 8.6. Hematology
  • 8.7. Immunology & Inflammation
  • 8.8. Infectious Diseases
  • 8.9. Musculoskeletal
  • 8.10. Neurology
  • 8.11. Oncology
  • 8.12. Ophthalmology

9. Cell & Gene Therapy Clinical Trials Market, by End-User

  • 9.1. Introduction
  • 9.2. Academic & Research Institutes
  • 9.3. Contract Research Organizations (CROs)
  • 9.4. Hospitals and Clinics
  • 9.5. Pharmaceutical Companies

10. Americas Cell & Gene Therapy Clinical Trials Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Cell & Gene Therapy Clinical Trials Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Cell & Gene Therapy Clinical Trials Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Cincinnati Children's launches USD 60 million Applied Gene and Cell Therapy Center in Sharonville
    • 13.3.2. Strategic partnership between Premier Research and BioCentriq accelerates pre-IND timelines and clinical translation of innovative cell therapies
    • 13.3.3. Astellas Pharma invests USD 50 million in Poseida Therapeutics for exclusive licensing and cancer cell therapy development
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Accell Clinical Research, LLC
  • 2. Alnylam Pharmaceuticals, Inc.
  • 3. Amgen Inc.
  • 4. Atlant Clinical Ltd.
  • 5. Biogen Inc.
  • 6. Charles River Laboratories International, Inc.
  • 7. CORESTEM, Inc.
  • 8. CTI Clinical Trial and Consulting Services, Inc.
  • 9. Dendreon Pharmaceuticals LLC
  • 10. HELIXMITH Co., Ltd.
  • 11. ICON PLC
  • 12. IQVIA Inc.
  • 13. Kolon TissueGene, Inc.
  • 14. Laboratory Corporation of America Holdings
  • 15. Medpace Holdings, Inc.
  • 16. Novartis AG
  • 17. Novotech Pty Limited
  • 18. Parexel International Corporation
  • 19. Ppd, Inc.
  • 20. ProPharma Group Holdings, LLC
  • 21. PSI CRO
  • 22. SGS S.A.
  • 23. Syneos Health, Inc.
  • 24. Veristat, LLC
  • 25. Wuxi AppTec Inc.

LIST OF FIGURES

  • FIGURE 1. CELL & GENE THERAPY CLINICAL TRIALS MARKET RESEARCH PROCESS
  • FIGURE 2. CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. CELL & GENE THERAPY CLINICAL TRIALS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. CELL & GENE THERAPY CLINICAL TRIALS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CELL & GENE THERAPY CLINICAL TRIALS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CELL & GENE THERAPY CLINICAL TRIALS MARKET DYNAMICS
  • TABLE 7. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY CLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ALLOGENEIC CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY AUTOLOGOUS CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CAR-T CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY MESENCHYMAL STEM CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY CLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE-BASED GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CRISPR-BASED GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE I, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE II, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE III, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE IV, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY DERMATOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ENDOCRINE, METABOLIC, & GENETIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GASTROENTEROLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY IMMUNOLOGY & INFLAMMATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY MUSCULOSKELETAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY OPHTHALMOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS (CROS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 51. ARGENTINA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 52. ARGENTINA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 53. ARGENTINA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 54. ARGENTINA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 55. BRAZIL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. BRAZIL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 57. BRAZIL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 58. BRAZIL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 59. BRAZIL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. BRAZIL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 61. CANADA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. CANADA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 63. CANADA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 64. CANADA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 65. CANADA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 66. CANADA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 67. MEXICO CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. MEXICO CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 69. MEXICO CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 70. MEXICO CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 71. MEXICO CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 72. MEXICO CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. UNITED STATES CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. UNITED STATES CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 75. UNITED STATES CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 76. UNITED STATES CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 77. UNITED STATES CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 78. UNITED STATES CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. UNITED STATES CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 87. AUSTRALIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. AUSTRALIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 89. AUSTRALIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 90. AUSTRALIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 91. AUSTRALIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. AUSTRALIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. CHINA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. CHINA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 95. CHINA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 96. CHINA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 97. CHINA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 98. CHINA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. INDIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. INDIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 101. INDIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 102. INDIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 103. INDIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. INDIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 105. INDONESIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. INDONESIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 107. INDONESIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 108. INDONESIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 109. INDONESIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 110. INDONESIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 111. JAPAN CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. JAPAN CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 113. JAPAN CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 114. JAPAN CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 115. JAPAN CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 116. JAPAN CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 117. MALAYSIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. MALAYSIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 119. MALAYSIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 120. MALAYSIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 121. MALAYSIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 122. MALAYSIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 123. PHILIPPINES CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. PHILIPPINES CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 125. PHILIPPINES CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 126. PHILIPPINES CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 127. PHILIPPINES CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 128. PHILIPPINES CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 129. SINGAPORE CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. SINGAPORE CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 131. SINGAPORE CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 132. SINGAPORE CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 133. SINGAPORE CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 134. SINGAPORE CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 135. SOUTH KOREA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. SOUTH KOREA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 137. SOUTH KOREA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 138. SOUTH KOREA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 139. SOUTH KOREA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 140. SOUTH KOREA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 141. TAIWAN CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. TAIWAN CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 143. TAIWAN CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 144. TAIWAN CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 145. TAIWAN CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 146. TAIWAN CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 147. THAILAND CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. THAILAND CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 149. THAILAND CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 150. THAILAND CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 151. THAILAND CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 152. THAILAND CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 153. VIETNAM CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. VIETNAM CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 155. VIETNAM CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 156. VIETNAM CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 157. VIETNAM CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 158. VIETNAM CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 166. DENMARK CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. DENMARK CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 168. DENMARK CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 169. DENMARK CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 170. DENMARK CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 171. DENMARK CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 172. EGYPT CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. EGYPT CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 174. EGYPT CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 175. EGYPT CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 176. EGYPT CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 177. EGYPT CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 178. FINLAND CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. FINLAND CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 180. FINLAND CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 181. FINLAND CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 182. FINLAND CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 183. FINLAND CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 184. FRANCE CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. FRANCE CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 186. FRANCE CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 187. FRANCE CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 188. FRANCE CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 189. FRANCE CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 190. GERMANY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. GERMANY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 192. GERMANY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 193. GERMANY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 194. GERMANY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 195. GERMANY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 196. ISRAEL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 197. ISRAEL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 198. ISRAEL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 199. ISRAEL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 200. ISRAEL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 201. ISRAEL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 202. ITALY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 203. ITALY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 204. ITALY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 205. ITALY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 206. ITALY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 207. ITALY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 208. NETHERLANDS CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 209. NETHERLANDS CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 210. NETHERLANDS CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 211. NETHERLANDS CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 212. NETHERLANDS CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 213. NETHERLANDS CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 214. NIGERIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 215. NIGERIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 216. NIGERIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 217. NIGERIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 218. NIGERIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 219. NIGERIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 220. NORWAY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. NORWAY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 222. NORWAY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 223. NORWAY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 224. NORWAY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 225. NORWAY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 226. POLAND CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 227. POLAND CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 228. POLAND CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 229. POLAND CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 230. POLAND CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 231. POLAND CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 232. QATAR CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 233. QATAR CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 234. QATAR CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 235. QATAR CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 236. QATAR CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 237. QATAR CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 238. RUSSIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 239. RUSSIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 240. RUSSIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 241. RUSSIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 242. RUSSIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 243. RUSSIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 244. SAUDI ARABIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 245. SAUDI ARABIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 246. SAUDI ARABIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 247. SAUDI ARABIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 248. SAUDI ARABIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 249. SAUDI ARABIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 250. SOUTH AFRICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 251. SOUTH AFRICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 252. SOUTH AFRICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 253. SOUTH AFRICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 254. SOUTH AFRICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 255. SOUTH AFRICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 256. SPAIN CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 257. SPAIN CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 258. SPAIN CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 259. SPAIN CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 260. SPAIN CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 261. SPAIN CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 262. SWEDEN CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 263. SWEDEN CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 264. SWEDEN CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 265. SWEDEN CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 266. SWEDEN CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 267. SWEDEN CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 268. SWITZERLAND CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 269. SWITZERLAND CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 270. SWITZERLAND CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 271. SWITZERLAND CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 272. SWITZERLAND CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 273. SWITZERLAND CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 274. TURKEY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 275. TURKEY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 276. TURKEY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 277. TURKEY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 278. TURKEY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 279. TURKEY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 280. UNITED ARAB EMIRATES CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 281. UNITED ARAB EMIRATES CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 282. UNITED ARAB EMIRATES CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 283. UNITED ARAB EMIRATES CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 284. UNITED ARAB EMIRATES CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 285. UNITED ARAB EMIRATES CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 286. UNITED KINGDOM CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 287. UNITED KINGDOM CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 288. UNITED KINGDOM CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 289. UNITED KINGDOM CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 290. UNITED KINGDOM CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)

TABLE 2